RY 173.64 -0.3672% SHOP 148.58 -0.6486% TD 82.36 -0.9263% ENB 64.21 -0.2641% BN 83.24 -1.0579% TRI 230.54 0.013% CNQ 46.58 3.4881% CP 109.8 1.4131% CNR 148.11 0.8031% BMO 143.82 0.3489% BNS 73.94 0.5029% CSU 4345.0 -1.0785% CM 90.555 -0.1158% MFC 44.31 0.113% ATD 76.82 0.0521% NGT 60.2 -0.1327% TRP 69.31 1.0939% SU 56.975 0.9658% WCN 255.98 -0.7868% L 181.13 -0.1268%
Last update at 2025-01-17T21:25:00Z
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally
Sun 19 Jan 25, 06:00 PMJim Cramer on Johnson & Johnson (JNJ): ‘Things Are Not Working Their Way’
Sun 19 Jan 25, 05:33 PM1 Stock to Buy, 1 Stock to Sell This Week: Netflix, Procter & Gamble
Sun 19 Jan 25, 03:04 PMTrump's inauguration looms as earnings season rolls on: What to know this week
Sun 19 Jan 25, 12:41 PMIs Johnson & Johnson (JNJ) the Best Cheap Stock to Buy for 2025?
Sun 19 Jan 25, 12:02 AMCount on Dividend King Pepsi (PEP) for Stability in a Volatile Market
Sat 18 Jan 25, 10:01 PMTariff threats, drug pricing will be 2 key pharma issues during Trump's first year
Sat 18 Jan 25, 05:31 PMWhy Is Cliff Asness Bullish On Johnson & Johnson (JNJ)?
Sat 18 Jan 25, 03:10 PM3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
Sat 18 Jan 25, 11:18 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 21725.00M | 22776.00M | 16497.00M | 17328.00M | 17999.00M |
| Minority interest | - | - | - | - | - |
| Net income | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Selling general administrative | 24765.00M | 24659.00M | 22084.00M | 22178.00M | 22540.00M |
| Selling and marketing expenses | - | - | 22084.00M | 22178.00M | 22540.00M |
| Gross profit | 63854.00M | 63920.00M | 54157.00M | 54503.00M | 54490.00M |
| Reconciled depreciation | 6970.00M | 7390.00M | 7231.00M | 7009.00M | 6929.00M |
| Ebit | 17054.00M | 18309.00M | 13111.00M | 15117.00M | 15623.00M |
| Ebitda | 24024.00M | 25699.00M | 20342.00M | 22126.00M | 22552.00M |
| Depreciation and amortization | 6970.00M | 7390.00M | 7231.00M | 7009.00M | 6929.00M |
| Non operating income net other | -1381.00000M | -436.00000M | -2788.00000M | -2168.00000M | -794.00000M |
| Operating income | 23917.00M | 24417.00M | 19824.00M | 21009.00M | 20781.00M |
| Other operating expenses | 71240.00M | 69228.00M | 62670.00M | 61089.00M | 60406.00M |
| Interest expense | 276.00M | 183.00M | 201.00M | 318.00M | 1005.00M |
| Tax provision | 3784.00M | 1898.00M | 1783.00M | 2209.00M | 2702.00M |
| Interest income | 490.00M | 53.00M | 111.00M | 357.00M | 611.00M |
| Net interest income | 214.00M | -130.00000M | -90.00000M | 39.00M | -394.00000M |
| Extraordinary items | - | - | 300.00M | - | - |
| Non recurring | 1104.00M | 1152.00M | 428.00M | 1156.00M | 1377.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 3784.00M | 1898.00M | 1783.00M | 2209.00M | 2702.00M |
| Total revenue | 94943.00M | 93775.00M | 82584.00M | 82059.00M | 81581.00M |
| Total operating expenses | 40151.00M | 39373.00M | 34243.00M | 33533.00M | 33315.00M |
| Cost of revenue | 31089.00M | 29855.00M | 28427.00M | 27556.00M | 27091.00M |
| Total other income expense net | -2192.00000M | -1641.00000M | -3327.00000M | -3681.00000M | -2782.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Net income applicable to common shares | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 187378.00M | 182018.00M | 174894.00M | 157728.00M | 152954.00M |
| Intangible assets | 48325.00M | 46392.00M | 53402.00M | 47643.00M | 47611.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3132.00M | 3701.00M | 3132.00M | 2486.00M | 3649.00M |
| Total liab | 110574.00M | 107995.00M | 111616.00M | 98257.00M | 93202.00M |
| Total stockholder equity | 76804.00M | 74023.00M | 63278.00M | 59471.00M | 59752.00M |
| Deferred long term liab | 6374.00M | 7487.00M | 7214.00M | 5958.00M | 7506.00M |
| Other current liab | 31328.00M | 30405.00M | 30357.00M | 26218.00M | 13257.00M |
| Common stock | 3120.00M | 3120.00M | 3120.00M | 3120.00M | 3120.00M |
| Capital stock | 3120.00M | 3120.00M | 3120.00M | 3120.00M | 3120.00M |
| Retained earnings | 128345.00M | 123060.00M | 113890.00M | 110659.00M | 106216.00M |
| Other liab | 26584.00M | 31784.00M | 35388.00M | 35083.00M | 34285.00M |
| Good will | 45231.00M | 35246.00M | 36393.00M | 33639.00M | 30453.00M |
| Other assets | 17049.00M | 17155.00M | 3896.00M | 11408.00M | 11305.00M |
| Cash | 14127.00M | 14487.00M | 13985.00M | 17305.00M | 18107.00M |
| Cash and equivalents | 5368.00M | 1901.00M | 2102.00M | 2864.00M | 3397.00M |
| Total current liabilities | 55802.00M | 45226.00M | 42493.00M | 35964.00M | 31230.00M |
| Current deferred revenue | - | - | - | 7819.00M | 7640.00M |
| Net debt | 25532.00M | 19264.00M | 21281.00M | 10391.00M | 12373.00M |
| Short term debt | 12771.00M | 3766.00M | 2631.00M | 1202.00M | 2796.00M |
| Short long term debt | 12771.00M | 3766.00M | 2631.00M | 1202.00M | 2796.00M |
| Short long term debt total | 39659.00M | 33751.00M | 35266.00M | 27696.00M | 30480.00M |
| Other stockholder equity | -41694.00000M | -39099.00000M | -38490.00000M | -38417.00000M | -34362.00000M |
| Property plant equipment | 19803.00M | 18962.00M | 18766.00M | 17658.00M | 17035.00M |
| Total current assets | 55294.00M | 60979.00M | 51237.00M | 45274.00M | 46033.00M |
| Long term investments | - | - | - | 1149.00M | 517.00M |
| Net tangible assets | -16752.00000M | -13073.00000M | -26517.00000M | -21811.00000M | -18312.00000M |
| Short term investments | 9392.00M | 17121.00M | 11200.00M | 1982.00M | 1580.00M |
| Net receivables | 16160.00M | 15283.00M | 13576.00M | 14481.00M | 14098.00M |
| Long term debt | 26888.00M | 29985.00M | 32635.00M | 26494.00M | 27684.00M |
| Inventory | 12483.00M | 10387.00M | 9344.00M | 9020.00M | 8599.00M |
| Accounts payable | 11703.00M | 11055.00M | 9505.00M | 8544.00M | 7537.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -12967.00000M | -13058.00000M | -15242.00000M | -15891.00000M | -15222.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 3120.00M | 3120.00M | 3120.00M | 3120.00M | 3120.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 128345.00M | 123060.00M | 113890.00M | 110659.00M | 106216.00M |
| Treasury stock | -41694.00000M | -39099.00000M | -38490.00000M | -38417.00000M | -34362.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 9602.00M | 10216.00M | 6562.00M | 5695.00M | -7909.00000M |
| Deferred long term asset charges | - | - | - | 7819.00M | 7640.00M |
| Non current assets total | 132084.00M | 121039.00M | 123657.00M | 112454.00M | 106921.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 26888.00M | 29985.00M | 32635.00M | 26494.00M | 27684.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 9225.00M | -5388.00000M | -8952.00000M | -533.00000M | -1337.00000M |
| Change to liabilities | -881.00000M | 1376.00M | 5885.00M | 5485.00M | 2107.00M |
| Total cashflows from investing activities | -12371.00000M | -8683.00000M | -20825.00000M | -6194.00000M | -3167.00000M |
| Net borrowings | 7452.00M | -990.00000M | 7095.00M | -2881.00000M | -3949.00000M |
| Total cash from financing activities | -8871.00000M | -14047.00000M | -6120.00000M | -18015.00000M | -18510.00000M |
| Change to operating activities | -1292.00000M | -3025.00000M | -2960.00000M | 371.00M | -2119.00000M |
| Net income | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Change in cash | -360.00000M | 502.00M | -3320.00000M | -802.00000M | 283.00M |
| Begin period cash flow | 14487.00M | 13985.00M | 17305.00M | 18107.00M | 17824.00M |
| End period cash flow | 14127.00M | 14487.00M | 13985.00M | 17305.00M | 18107.00M |
| Total cash from operating activities | 21194.00M | 23410.00M | 23536.00M | 23416.00M | 22201.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 6970.00M | 7390.00M | 7231.00M | 7009.00M | 6929.00M |
| Other cashflows from investing activities | -17587.00000M | 357.00M | -8526.00000M | -2163.00000M | 1840.00M |
| Dividends paid | -11682.00000M | -11032.00000M | -10481.00000M | -9917.00000M | 9494.00M |
| Change to inventory | -2527.00000M | -1248.00000M | -265.00000M | -277.00000M | -644.00000M |
| Change to account receivables | -1290.00000M | -2402.00000M | 774.00M | -289.00000M | -1185.00000M |
| Sale purchase of stock | -6035.00000M | -3456.00000M | -3221.00000M | -6746.00000M | -5868.00000M |
| Other cashflows from financing activities | 17530.00M | 395.00M | -627.00000M | 575.00M | -148.00000M |
| Change to netincome | 294.00M | -620.00000M | -1099.00000M | -2577.00000M | -28.00000M |
| Capital expenditures | 4009.00M | 3652.00M | 3347.00M | 3498.00M | 3670.00M |
| Change receivables | -1290.00000M | -2402.00000M | 774.00M | -289.00000M | -1185.00000M |
| Cash flows other operating | 687.00M | -1964.00000M | -3704.00000M | -1054.00000M | -275.00000M |
| Exchange rate changes | - | - | - | - | -241.00000M |
| Cash and cash equivalents changes | -48.00000M | 680.00M | -3409.00000M | -793.00000M | 283.00M |
| Change in working capital | -4011.00000M | -4238.00000M | 2690.00M | 3865.00M | 3.00M |
| Stock based compensation | 1138.00M | 1135.00M | 1005.00M | 977.00M | 978.00M |
| Other non cash items | 819.00M | 324.00M | -963.00000M | -1078.00000M | 10.00M |
| Free cash flow | 17185.00M | 19758.00M | 20189.00M | 19918.00M | 18531.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson |
-0.74 0.50% | 147.03 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| LLY Eli Lilly and Company |
-31.88 4.21% | 725.72 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| ABBV AbbVie Inc |
-2.14 1.23% | 171.56 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
-2.78 2.76% | 97.92 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| AZN AstraZeneca PLC ADR |
-0.31 0.46% | 66.60 | 38.69 | 16.31 | 4.67 | 5.46 | 5.20 | 17.74 |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
| Name | Title | Year Born |
|---|---|---|
| Mr. Alex Gorsky | Exec. Chairman | 1960 |
| Mr. Joaquin Duato | CEO & Director | 1963 |
| Mr. Joseph J. Wolk CPA | Exec. VP & CFO | 1967 |
| Ms. Jennifer L. Taubert | Exec. VP & Worldwide Chairman of Pharmaceuticals | 1964 |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | 1972 |
| Mr. James Swanson | Exec. VP & Chief Information Officer | NA |
| Ms. Jessica Moore | VP of Investor Relations | NA |
| Mr. Dirk Brinckman | Chief Compliance Officer | NA |
| Ms. Elizabeth Forminard | Exec. VP & Gen. Counsel | NA |
| Dr. Peter M. Fasolo Ph.D. | Exec. VP & Chief HR Officer | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...